Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency
Phase of Trial: Phase I/II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs ADVM 043 (Primary) ; ADVM 043 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; First in man
- Acronyms ADVANCE
- Sponsors Adverum Biotechnologies
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.
- 08 Nov 2017 According to an Adverum Biotechnologies media release, the Company plans to begin patient enrollment in this trial in the fourth quarter of 2017. The Company expects to report preliminary data from this trial in the second half of 2018.
- 05 Oct 2017 Status changed from planning to not yet recruiting.